QCLS · Q/C Technologies, Inc.
$2.49
+0.05 (+2.05%)
At close · Aug 26
Market Cap
$20.39M
Shares
8.19M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Christopher Chapman | Former President, Chief Medical Officer | $420,385 |
| Mitchell Glass | President, Chief Medical Officer | $182,333 |
| Ian Rhodes | Interim Chief Financial Officer | $162,000 |
| Adam Kaplin | M.D., PhD Former Chief Scientific Officer | $78,131 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Christopher Chapman | Former President, Chief Medical Officer | $2,884,326 |
| Adam Kaplin | M.D., Ph.D. Former Chief Scientific Officer | $593,995 |
| Paul Rivard | Former Chief Legal Officer | $578,273 |
| Ian Rhodes | Interim Chief Financial Officer | $162,000 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Adam Kaplin | M.D., Ph.D. Former Chief Scientific Officer | $353,733 |
| Christopher Chapman | Former President, Chief Medical Officer | $261,827 |
| Paul Rivard | Former Chief Legal Officer | $188,239 |
| Ian Rhodes | Interim Chief Financial Officer | $162,000 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Adam Kaplin | M.D., PhD Chief Scientific Officer | $5,230,724 |
| Christopher Chapman | President, Chief Medical Officer | $5,140,540 |
| Paul Rivard | Chief Legal Officer | $1,843,000 |
| Christopher C. Schreiber | Former President and Chief Executive Officer | $1,513,500 |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| Christopher C. Schreiber | Former President and Chief Executive Officer | $1,097,858 |
| Adam Kaplin | M.D., PhD Chief Scientific Officer | $360,833 |
| Christopher Chapman | President, Chief Medical Officer | $297,500 |
| Paul Rivard | Esq., Executive Vice President of Operations and General Counsel | $175,000 |
Fiscal 2019
| Executive | Role | Total |
|---|---|---|
| Howard R. Yeaton | — | $326,302 |
| Christopher C. Schreiber | — | $50,000 |
Fiscal 2018
| Executive | Role | Total |
|---|---|---|
| Howard R. Yeaton | — | $92,715 |
| Christopher C. Schreiber | — | — |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Chelsea Voss | member of the board of directors | Appointed | 2026-01-23 |
| Joshua Silverman | Executive Chairman | Appointed | 2025-09-02 |
| Bruce Bernstein | Board | Appointed | 2025-09-02 |
| Mitchell Glass | President | Resigned | 2025-09-02 |
| Jude Uzonwanne | member of the board of directors | Resigned | 2025-09-02 |
| Stephen Friscia | director | Appointed | 2024-11-26 |
| Bill J. White | director | Appointed | 2024-11-26 |
| Jude Uzonwanne | director | Appointed | 2024-11-26 |
| Joshua Silverman | director | Appointed | 2024-11-26 |
| Craig Eagle | director | Appointed | 2024-11-26 |
| Christopher C. Schreiber | director | Appointed | 2024-11-26 |
| Mitchell Glass | director | Appointed | 2024-11-26 |
| Christopher Chapman, M.D. | member of the board of directors | Resigned | 2024-06-17 |
| Stephen Friscia | member of the Board | Appointed | 2024-06-17 |
| Christopher Chapman, M.D. | Chief Medical Officer | Resigned | 2024-06-17 |
| Christopher Chapman, M.D. | President | Resigned | 2024-06-17 |
| Adam Kaplin, M.D., Ph.D. | Chief Scientific Officer | Resigned | 2024-04-18 |
| Mitchell Glass | member of the Company's board of directors | Appointed | 2024-04-08 |
| Paul Rivard, Esq. | Chief Legal Officer | Appointed | 2023-03-23 |
| Robert C. Schroeder | member of the board of directors | Terminated | 2021-09-03 |
| Paul Rivard | Executive Vice President of Operations and General Counsel | Appointed | 2021-04-22 |
| Jude Uzonwanne | Director | Appointed | 2021-04-22 |
| Chris Chapman | President and Chief Medical Officer | Appointed | 2021-04-22 |
| Adam Kaplin | Chief Scientific Officer | Appointed | 2021-04-22 |
| Craig Eagle | Director | Appointed | 2021-04-22 |
Key facts
CIK
1321834
CUSIP
62856X300
13F (30d)
20 filings
20 filers
Visit website
Investor relations